Q-Med AB invites to conference call regarding half year report January-June, 2009

Time: Thursday, July 23, 2009 at 11.30 a.m. CET. To join the conference: Swedish dial in number: + 46 (0)8 5052 0114 UK dial in number: +44 (0)207 1620 177 Q-Med participants: Bengt Ågerup, CEO Alexander Kotsinas, CFO Karin Falck, Director Corporate Communications Q-Med AB’s Q2 report will be released approximately 10.30 on July 23, 2009. The slide presentation will be available at www.q-med.com, and Investors/Presentations. A recorded version of the presentation will be available for seven working days on tel: Sweden +46 (0)8 505 203 33 or UK +44 (0)20 7031 4064, access code: 83 99 40. Financial information from Q-Med during 2009 23 October Interim Report January – September 2009 Queries should be addressed to: Karin Falck, Director Corporate Communications Tel: +46 70 974 90 15 Kristin Ermanbriks, Manager Corporate Administration Tel; +46 70 974 90 71 Q-Med AB is a medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, NASHA™, for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: Restylane® for filling lines and folds, contouring and creating volume in the face, Macrolane™ for body contouring, Durolane™ for the treatment of osteoarthritis of the hip and knee joints, Deflux® for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and Solesta™ for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q Med today has about 650 coworkers, with approximately 400 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic. Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882. Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail: info@q-med.com. Web: www.q-med.com.